Josh Mandel-Brehm
Directeur/Membre du Conseil chez PROMIS NEUROSCIENCES, INC.
Fortune : - $ au 31/05/2024
Profil
Josh Mandel-Brehm is a Director at Vico Therapeutics BV, which he founded in 2019.
He is currently the President, Chief Executive Officer & Director at Camp4 Therapeutics Corp.
since 2017 and an Independent Director at ProMIS Neurosciences, Inc. since 2021.
Mr. Mandel-Brehm completed his undergraduate degree at Washington University in St. Louis and his MBA at the University of Michigan.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Josh Mandel-Brehm
| Sociétés | Poste | Début |
|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Directeur/Membre du Conseil | 01/09/2021 |
Camp4 Therapeutics Corp.
 Camp4 Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom. | Directeur Général | 01/05/2017 |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Fondateur | 01/09/2019 |
Formation de Josh Mandel-Brehm
| University of Michigan | Masters Business Admin |
| Washington University in St. Louis | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Camp4 Therapeutics Corp.
Camp4 Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Health Technology |
